Quick Answer
ArriVent BioPharma, Inc. reported Stockholders Equity of $307.22 million for the year ending 2025.
- ArriVent BioPharma, Inc. showed an increase of +19.2% in Stockholders Equity from 2024 to 2025.
- This data is from ArriVent BioPharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$97.09 million | Q2 2023: -$118.46 million | Q3 2023: -$132.60 million | Q1 2024: $317.72 million | Q2 2024: $296.66 million | Q3 2024: $277.49 million | Q1 2025: $202.54 million | Q2 2025: $249.87 million | Q3 2025: $305.00 million.
- Over the full 4 years of available data (2022 to 2025), ArriVent BioPharma, Inc.'s Stockholders Equity has grown by 461.0%.
- Historical annual values: Fiscal year 2025: $307.22 million | Fiscal year 2024: $257.65 million | Fiscal year 2023: -$153.19 million | Fiscal year 2022: -$85.11 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: